CN115349585A - Composite prebiotic composition for regulating human intestinal function, preparation process and application thereof - Google Patents
Composite prebiotic composition for regulating human intestinal function, preparation process and application thereof Download PDFInfo
- Publication number
- CN115349585A CN115349585A CN202211070558.8A CN202211070558A CN115349585A CN 115349585 A CN115349585 A CN 115349585A CN 202211070558 A CN202211070558 A CN 202211070558A CN 115349585 A CN115349585 A CN 115349585A
- Authority
- CN
- China
- Prior art keywords
- parts
- prebiotic composition
- fruit
- regulating
- intestinal function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 60
- 230000003871 intestinal function Effects 0.000 title claims abstract description 45
- 239000002131 composite material Substances 0.000 title claims abstract description 41
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000006041 probiotic Substances 0.000 claims abstract description 43
- 235000018291 probiotics Nutrition 0.000 claims abstract description 43
- 230000000529 probiotic effect Effects 0.000 claims abstract description 39
- 239000011259 mixed solution Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 47
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 44
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 39
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 24
- 229920001100 Polydextrose Polymers 0.000 claims description 22
- 238000000855 fermentation Methods 0.000 claims description 22
- 230000004151 fermentation Effects 0.000 claims description 22
- 239000001259 polydextrose Substances 0.000 claims description 22
- 235000013856 polydextrose Nutrition 0.000 claims description 22
- 229940035035 polydextrose Drugs 0.000 claims description 22
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 21
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 21
- 229920001285 xanthan gum Polymers 0.000 claims description 21
- 235000010493 xanthan gum Nutrition 0.000 claims description 21
- 239000000230 xanthan gum Substances 0.000 claims description 21
- 229940082509 xanthan gum Drugs 0.000 claims description 21
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 20
- 229920002498 Beta-glucan Polymers 0.000 claims description 20
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 20
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 20
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 18
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 14
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- 235000015203 fruit juice Nutrition 0.000 claims description 14
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 14
- 238000004537 pulping Methods 0.000 claims description 14
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 13
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 13
- 240000001008 Dimocarpus longan Species 0.000 claims description 13
- 235000000235 Euphoria longan Nutrition 0.000 claims description 13
- 244000199866 Lactobacillus casei Species 0.000 claims description 13
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 13
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 13
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 13
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 13
- 244000182216 Mimusops elengi Species 0.000 claims description 13
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 13
- 240000000249 Morus alba Species 0.000 claims description 13
- 235000008708 Morus alba Nutrition 0.000 claims description 13
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 13
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 13
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 13
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 13
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 13
- 235000021014 blueberries Nutrition 0.000 claims description 13
- 229940017800 lactobacillus casei Drugs 0.000 claims description 13
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 8
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 3
- -1 isomaltose oligosaccharide Chemical class 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 22
- 208000008589 Obesity Diseases 0.000 abstract description 20
- 235000020824 obesity Nutrition 0.000 abstract description 20
- 230000009286 beneficial effect Effects 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 10
- 230000035755 proliferation Effects 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 235000013325 dietary fiber Nutrition 0.000 abstract description 9
- 206010012735 Diarrhoea Diseases 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 8
- 206010016766 flatulence Diseases 0.000 abstract description 6
- 210000002540 macrophage Anatomy 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 230000004888 barrier function Effects 0.000 abstract description 4
- 230000007124 immune defense Effects 0.000 abstract description 4
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 4
- 210000000822 natural killer cell Anatomy 0.000 abstract description 4
- 235000005911 diet Nutrition 0.000 abstract description 3
- 230000037213 diet Effects 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 description 19
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 241000186000 Bifidobacterium Species 0.000 description 11
- 241001092040 Crataegus Species 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 210000000577 adipose tissue Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 108050008546 Hyperglycemic hormone Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241001647875 Pseudoxanthomonas Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 241001148118 Xanthomonas sp. Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010564 aerobic fermentation Methods 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000670 co-carcinogen Toxicity 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/84—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter using microorganisms or biological material, e.g. enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The application provides a composite prebiotic composition for regulating human intestinal functions, a preparation process and an application thereof, and relates to the field of special diet. The composite prebiotic composition comprises a plurality of dietary fibers, the balance of the product on the proliferation of intestinal flora and the flora structure is improved by the dietary fibers, the stability of an intestinal mucosa barrier is increased, the functions of macrophages and natural killer cells are enhanced, the immune defense capability of a human body is improved, obesity is prevented and controlled, the occurrence of obesity complications is reduced, and adverse reactions such as diarrhea and flatulence cannot occur in the taking process. The liquid preparation is convenient to take and is more beneficial to absorption. In the preparation process, the mixed solution is treated by a micro-jet device, so that the dispersibility and the associativity of each component in the probiotic composition can be improved, and the intestinal function regulation of the probiotic composition is further improved.
Description
Technical Field
The application relates to the field of special diet, in particular to a composite prebiotic composition for regulating human intestinal functions, a preparation process and an application thereof.
Background
Diseases of the digestive system and imbalance of intestinal flora interact with each other in cause and effect, and under a normal physiological state, the colonic flora can ferment nondigestible food residues and metabolize endogenous mucus produced by epithelial cells, so as to generate absorbable nutrients and energy for a host and promote the growth and proliferation of bacteria per se. The intestinal dominant flora can inhibit colonization of the intestinal dominant flora by competing nutrition, and simultaneously produce bacteriocin, short-chain fatty acid and other substances to degrade pathogen toxin and reduce the toxicity of the pathogen toxin. Fermentation is abnormally active in the cecum and right-half colon (especially in the ileocecal region) and produces large amounts of short chain fatty acids such as acetic acid, propionic acid and butyric acid, which are almost completely consumed by colonic epithelial cells and are the main energy source of the colon; short chain fatty acids also delay the onset and progression of chronic ulcerative colitis, inhibit the formation of carcinogens or co-carcinogens, convert certain carcinogens to non-carcinogens, activate macrophages, reduce the incidence of colon cancer, etc., by which mechanisms microorganisms exert their beneficial or adverse effects, and further research is needed.
At present, two methods for adjusting the intestinal micro-ecological environment exist, namely probiotic bacteria supplementation. Normal intestinal flora, in particular bifidobacteria, lactic acid bacteria and the like have important effects on maintaining a good intestinal flora structure and the health of organisms, but live bacteria supplement bacteria have a plurality of defects in the aspects of colonization ability, live bacteria survival rate, transportation, storage and the like; and the second is the self enrichment of probiotics in the intestinal tract, namely the prebiotics supplement. The physiological function of prebiotics is realized mainly by promoting the reproduction of beneficial bacteria in the intestines and regulating the microecological balance in the intestines, and is shown in the aspects of improving the functions of the intestines, enhancing the immunity of organisms and the like.
Although prebiotic products are already available on the market, many products have single components, and have adverse reactions such as diarrhea, flatulence and the like after being taken.
Disclosure of Invention
The application aims to provide a compound prebiotics composition for adjusting human intestinal functions, multiple dietary fibers not only promote the proliferation of products to intestinal flora and the balance of flora structures, but also increase the stability of intestinal mucosa barriers, strengthen the functions of macrophages and natural killer cells, further promote the immune defense capability of human bodies, further prevent and control obesity, reduce the occurrence of obesity complications, and avoid adverse reactions such as diarrhea and flatulence in the taking process.
Another object of the present application is to provide a preparation of a complex prebiotic composition for regulating intestinal function of a human body, wherein the preparation of the complex prebiotic composition is a liquid preparation. The liquid preparation is convenient to take and is more beneficial to absorption.
Another objective of the present application is to provide a preparation process of a composite probiotic composition for regulating intestinal function of a human body, wherein the mixed solution is processed by a micro-jet device, so as to improve dispersibility and associativity of each component in the probiotic composition, thereby further improving the intestinal function regulation of the probiotic composition.
Another object of the present application is to provide a use of a complex prebiotic composition for regulating intestinal function of a human body in the preparation of a food and/or health care product for regulating intestinal function of a human body. Can effectively regulate the intestinal function of human body, influence the metabolism of host by regulating intestinal flora, further prevent and control obesity and reduce obesity complications.
The technical problem to be solved by the application is solved by adopting the following technical scheme.
The embodiment of the application provides a composite prebiotic composition for regulating the intestinal function of a human body, which comprises the following raw materials in parts by weight: 40-60 parts of probiotic ferment fruit and vegetable juice, 20-30 parts of polydextrose, 20-25 parts of xylooligosaccharide, 20-25 parts of isomaltooligosaccharide, 15-20 parts of stachyose, 10-15 parts of chitosan oligosaccharide, 10-12 parts of yeast beta-glucan, 8-10 parts of xanthan gum and 3-5 parts of edible essence.
Secondly, the embodiment of the application provides a preparation of the composite prebiotic composition, and the preparation of the composite prebiotic composition is a liquid preparation.
Third, the embodiment of the present application provides a preparation process of a composite prebiotic composition for regulating intestinal function of a human body, comprising the following steps:
step A: selecting fresh and non-rotten red dates, medlar, longan, mulberry, blueberry and hawthorn, cleaning, pulping into juice by using a pulping machine, filtering by using a 80-mesh filter screen to obtain composite fruit juice, and sterilizing the fruit juice at 105-110 ℃ for 10-30s to obtain fruit and vegetable juice;
and B: respectively activating and culturing lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis, and then carrying out expanded culture to obtain fermentation liquor of each strain;
and C: uniformly stirring the fruit and vegetable juice and fermentation liquor of each strain, standing for fermentation to obtain probiotic ferment fruit and vegetable juice, adding polydextrose, xylooligosaccharide, isomaltooligosaccharide, stachyose, chitosan oligosaccharide, yeast beta-glucan, xanthan gum and edible essence, uniformly mixing to obtain a mixed solution, adding the mixed solution into a micro-jet device for treatment for 2 times, filtering the mixed solution after homogenization, and subpackaging filtrate to obtain the composite prebiotic composition.
Fourth, the embodiment of the present application provides an application of a complex prebiotic composition in the preparation of food and/or health care products for regulating intestinal function of human body.
Compared with the prior art, the embodiment of the application has at least the following advantages or beneficial effects:
first, the embodiment of the application provides a composite prebiotic composition for regulating human intestinal functions, which contains a plurality of dietary fibers, wherein the dietary fibers not only promote the proliferation of intestinal flora and the balance of flora structure, but also increase the stability of intestinal mucosa barrier, strengthen the functions of macrophages and natural killer cells, further improve the immune defense capability of human body, further prevent and control obesity, reduce obesity complications, and avoid adverse reactions such as diarrhea and flatulence during administration.
Second, the present application provides a formulation of a complex prebiotic composition, which is a liquid formulation. The liquid preparation is convenient to take and is more beneficial to absorption.
Thirdly, the embodiment of the application provides a preparation process of the composite probiotic composition for regulating the intestinal function of the human body, the mixed liquid is processed by a micro-jet device, and the dispersibility and the associativity of each component in the probiotic composition can be improved, so that the intestinal function regulation of the probiotic composition is further improved.
Fourth, the embodiment of the present application provides an application of a complex prebiotic composition in the preparation of food and/or health care products for regulating intestinal function of human body. Can effectively regulate the intestinal function of human body, influence the metabolism of host by regulating intestinal flora, further prevent and control obesity and reduce the occurrence of obesity complications.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions of the embodiments of the present application will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that, in the present application, the embodiments and features of the embodiments may be combined with each other without conflict. The present application will be described in detail below with reference to specific examples.
The embodiment of the application provides a composite prebiotic composition for regulating the intestinal function of a human body, which comprises the following raw materials in parts by weight: 40-60 parts of probiotic ferment fruit and vegetable juice, 20-30 parts of polydextrose, 20-25 parts of xylooligosaccharide, 20-25 parts of isomaltooligosaccharide, 15-20 parts of stachyose, 10-15 parts of chitosan oligosaccharide, 10-12 parts of yeast beta-glucan, 8-10 parts of xanthan gum and 3-5 parts of edible essence.
Prebiotics in the probiotic ferment fruit and vegetable juice protect intestinal barriers and promote the growth of beneficial bacteria, and the dysbacteriosis in intestinal tracts is relieved; can relieve endotoxemia caused by intestinal flora disorder, recover intestinal flora, and especially increase content of Bifidobacterium related to obesity.
Polydextrose is a water-soluble dietary fiber. Is capable of regulating lipid metabolism: polydextrose can form a film in the small intestine and wrap part of food fat, so that the absorption of fat in the digestive tract can be effectively limited, the excretion of lipid compounds can be promoted, the satiety can be increased, and the food intake can be reduced, thereby achieving the effects of regulating blood fat, reducing fat accumulation, preventing obesity and the like; reducing sugar absorption: polydextrose can prevent food from fully contacting digestive juice, inhibit secretion of hyperglycemic hormone, and promote glucose absorption to slow down, so as to reduce postprandial blood glucose level, fully exert insulin effect, and prevent diabetes; preventing and treating constipation: the polydextrose can absorb water and swell in human intestinal tracts, keep water, increase the volume of excrement, stimulate intestinal peristalsis, accelerate defecation frequency, and play a role in relaxing bowel and preventing constipation.
Xylo-oligosaccharide, as a novel functional food, has unique advantages, and can selectively promote the proliferation activity of intestinal bifidobacteria. The bifidus factor function is 10-20 times of other polymeric saccharides (prebiotics); the abundance of beneficial bacteria is remarkably increased, the integral proportion of beneficial bacteria is improved, and the intestinal microecology is activated; is an excellent nutrient source and effective proliferation factor of beneficial bacteria such as bifidobacterium, lactobacillus acidophilus and the like in human intestinal tracts, and can improve the functions of the human intestinal tracts.
The isomaltose hypgather is difficult to be digested by gastric enzyme, has low sweetness and low calorie, and does not basically increase blood sugar and blood fat. The isomaltose hypgather product contains no monosaccharide or very low monosaccharide, and the heat energy is only 1/6 of that of sucrose. The isomaltooligosaccharide is difficult to decompose and absorb by digestive enzyme, and the control experiment with the glucose-only oral population proves that the blood sugar and the insulin of the fasting oral isomaltooligosaccharide population are not increased, which indicates that the isomaltooligosaccharide is not absorbed and utilized in the stomach and completely enters the intestinal tract. Therefore, if the health food is eaten for a long time, the blood sugar is not increased, the insulin level in blood is not changed, and the diabetes patient can eat the health food with confidence. Isomaltose hypgather can promote the proliferation of bifidobacteria in intestinal tracts, inhibit the formation of harmful bacteria and putrefactive substances in the intestinal tracts, increase the content of vitamins and improve the immunity of organisms. The isomaltooligosaccharide can not be absorbed by stomach and small intestine, but directly enters large intestine, is preferentially utilized by bifidobacterium to help the bifidobacterium to propagate in large quantity, and is a bifidobacterium propagation factor; other harmful bacteria in the intestines cannot be utilized, so that the growth of the harmful bacteria can be inhibited, and the microecology in the intestines can be adjusted to a benign cycle. Such as: (1) maintaining a normal balance of the bacterial flora in the intestine, especially in elderly and infants. Bifidobacterium can inhibit the growth of pathogenic bacteria and putrefying bacteria, and prevent constipation, diarrhea and gastrointestinal disorder. (2) Bifidobacterium has antitumor activity. (3) The bifidobacterium can synthesize vitamins B1, B2, B6, K, nicotinic acid, folic acid and the like and certain amino acids in the intestinal tract, and improve the absorption of calcium ions. (4) Reducing blood cholesterol level, and preventing and treating hypertension. (5) Improve the digestibility of the dairy products and improve the lactose resistance. Many dairy products abroad are added with the malto-oligosaccharide to improve the health care function of the dairy products. (6) Enhancing immunity, and preventing various adverse side effects of antibiotics.
Stachyose is a natural substance extracted from plant, can completely enter colon and be fermented by intestinal beneficial bacteria, can obviously promote the proliferation of the intestinal beneficial bacteria, and is a special nutrient source for the intestinal beneficial bacteria. Meanwhile, stachyose has unique dual functions as soluble dietary fiber, has high viscosity and high water absorption capacity, and can quickly balance water in the digestive tract, thereby inhibiting diarrhea.
Chitosan oligosaccharide can not be degraded by a host enzyme system, enters a back-end intestinal tract, is selectively utilized by probiotics, promotes the growth of the probiotics, can be adsorbed on the surface of pathogenic bacteria, interferes with cell wall synthesis, and is degraded by chitosan to obtain dead chitosan oligosaccharide, which is animal prebiotics from shrimp and crab shells and can act synergistically with plant prebiotics.
Specifically, in other examples of the present application, chitosan oligosaccharide with molecular weight below 1500Da and polymerization degree of 2-10 is selected, and its bioactivity is high.
The yeast beta-glucan is a polysaccharide with the activity of enhancing immunity, namely the beta-glucan, existing in yeast cell walls. The special ultramicro spiral molecular structure is the form which has the strongest immune activity and is most easily absorbed by human bodies; the yeast glucan is a main component of yeast cell walls, is completely extracted from yeast, and is natural and safe; the biological activity is high: has strong biological activity of enhancing immunity, resisting radiation and reducing blood fat; can effectively regulate the micro-ecology of the digestive tract in vivo, and promote the proliferation of beneficial bacteria in vivo and the excretion of harmful substances in intestinal tract; can improve the feeling of peripheral tissues on insulin, reduce the requirement on insulin, promote the recovery of glucose and have obvious effects of inhibiting and preventing diabetes.
Xanthan gum is also called xanthan gum, xanthomonas polysaccharide, is a kind of monospore polysaccharide produced by fermentation of pseudoxanthomonas, is an acidic extracellular heteropolysaccharide composed of straight chain synthesized by using carbohydrate as main raw material by aerobic fermentation bioengineering technology from Xanthomonas campestris of cabbage black rot. Xanthan gum is an extracellular microbial polysaccharide produced by fermentation of saccharides with xanthomonas sp. Due to the special structure and colloid characteristics of macromolecules, the modified starch has multiple functions and can be used as an emulsifier, a stabilizer, a gel thickener, a sizing agent, a film forming agent and the like.
In some embodiments of the present application, the probiotic ferment fruit and vegetable juice comprises the following raw materials: red date, longan, medlar, mulberry, blueberry, hawthorn, lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis.
The prebiotics can obviously reduce the low-density lipoprotein content of obese people and increase the high-density lipoprotein content; the composition can reduce obesity index of obesity model of obese patients, control weight, improve dyslipidemia, and relieve liver lipid metabolism disorder to a certain extent, and the action mechanism of the composition can influence the metabolism of a host by regulating intestinal flora, so as to prevent and control obesity and reduce obesity complications.
In some embodiments of the present application, the composite prebiotic composition comprises the following raw materials in parts by weight: 40 parts of probiotic ferment fruit and vegetable juice, 20 parts of polydextrose, 20 parts of xylooligosaccharide, 20 parts of isomaltooligosaccharide, 15 parts of stachyose, 10 parts of chitosan oligosaccharide, 10 parts of yeast beta-glucan, 8 parts of xanthan gum and 3 parts of edible essence.
In some embodiments of the present application, the composite prebiotic composition comprises the following raw materials in parts by weight: 60 parts of probiotic ferment fruit and vegetable juice, 30 parts of polydextrose, 25 parts of xylooligosaccharide, 25 parts of isomaltooligosaccharide, 20 parts of stachyose, 15 parts of chitosan oligosaccharide, 12 parts of yeast beta-glucan, 10 parts of xanthan gum and 5 parts of edible essence.
Second, the present application provides a formulation of a complex prebiotic composition, which is a liquid formulation.
Third, the embodiment of the present application provides a preparation process of a composite prebiotic composition for regulating human intestinal function, which comprises the following steps:
step A: selecting fresh and non-rotten red dates, medlar, longan, mulberry, blueberry and hawthorn, cleaning, pulping into juice by using a pulping machine, filtering by using a 80-mesh filter screen to obtain composite fruit juice, and sterilizing the fruit juice at 105-110 ℃ for 10-30s to obtain fruit and vegetable juice;
and B: respectively activating and culturing lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis, and then carrying out expanded culture to obtain fermentation liquor of each strain;
and C: uniformly stirring the fruit and vegetable juice and fermentation liquor of each strain, standing for fermentation to obtain probiotic ferment fruit and vegetable juice, adding polydextrose, xylooligosaccharide, isomaltooligosaccharide, stachyose, chitosan oligosaccharide, yeast beta-glucan, xanthan gum and edible essence, uniformly mixing to obtain a mixed solution, adding the mixed solution into a micro-jet device for treatment for 2 times, filtering the mixed solution after homogenization, and subpackaging filtrate to obtain the composite prebiotic composition.
In some embodiments of the present application, the activation culture is performed at 30-37 deg.C for 36-48h in step B.
In some embodiments of the present application, the condition of the scale-up culture in step B is 32-38 ℃ for 60-72h.
In some embodiments of the present application, the conditions of the standing fermentation in step C are: the temperature is 23-25 ℃, and the time is 24-36h.
Fourth, the embodiment of the present application provides an application of a complex prebiotic composition in the preparation of food and/or health care products for regulating intestinal functions of human body.
The features and properties of the present application are described in further detail below with reference to examples.
Example 1
The embodiment of the application provides a composite prebiotics composition for adjusting human intestinal functions, which comprises the following raw materials in parts by weight: 60g of probiotic ferment fruit and vegetable juice, 30g of polydextrose, 25g of xylooligosaccharide, 25g of isomaltooligosaccharide, 20g of stachyose, 15g of chitosan oligosaccharide, 12g of yeast beta-glucan, 10 parts of xanthan gum and 5g of edible essence.
The probiotic ferment fruit and vegetable juice comprises the following raw materials: red date, longan, medlar, mulberry, blueberry, hawthorn, lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis.
The embodiment of the application provides a preparation process of a composite prebiotic composition for regulating the intestinal function of a human body, which comprises the following steps:
step A: selecting fresh and non-rotten red dates, medlar, longan, mulberry, blueberry and hawthorn, cleaning, pulping into juice by using a pulping machine, filtering by using a 80-mesh filter screen to obtain composite fruit juice, and sterilizing the fruit juice at 105-110 ℃ for 10-30s to obtain fruit and vegetable juice;
and B: respectively performing activated culture on lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis at 37 ℃ for 36 hours, and performing expanded culture at 38 ℃ for 60 hours to obtain fermentation liquor of each strain;
and C: stirring the fruit and vegetable juice and the fermentation liquor of each strain uniformly, standing and fermenting for 24-36h at 25 ℃ to obtain probiotic ferment fruit and vegetable juice, adding polydextrose, xylooligosaccharide, isomaltose hypgather, stachyose, chitosan oligosaccharide, yeast beta-glucan, xanthan gum and edible essence, mixing uniformly to obtain a mixed solution, adding the mixed solution into a micro-jet device for treatment for 2 times, filtering the mixed solution after homogenization, and subpackaging the filtrate to obtain the composite prebiotic composition.
Example 2
The embodiment of the application provides a composite prebiotic composition for adjusting human intestinal function, which comprises the following raw materials in parts by weight: 50g of probiotic ferment fruit and vegetable juice, 25g of polydextrose, 23g of xylooligosaccharide, 23g of isomaltooligosaccharide, 18g of stachyose, 13g of chitosan oligosaccharide, 11g of yeast beta-glucan, 9 parts of xanthan gum and 4g of edible essence.
The probiotic ferment fruit and vegetable juice comprises the following raw materials: red date, longan, medlar, mulberry, blueberry, hawthorn, lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis.
The embodiment of the application provides a preparation process of a composite prebiotic composition for regulating the intestinal function of a human body, which comprises the following steps:
step A: selecting fresh and non-rotten red dates, medlar, longan, mulberry, blueberry and hawthorn, cleaning, pulping into juice by using a pulping machine, filtering by using a 80-mesh filter screen to obtain composite fruit juice, and sterilizing the fruit juice at 105-110 ℃ for 10-30s to obtain fruit and vegetable juice;
and B: respectively performing activation culture on lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis at 35 ℃ for 40h, and performing amplification culture at 36 ℃ for 66h to obtain fermentation liquor of each strain;
and C: stirring the fruit and vegetable juice and the fermentation liquor of each strain uniformly, standing and fermenting for 24-36h at 24 ℃ to obtain probiotic ferment fruit and vegetable juice, adding polydextrose, xylooligosaccharide, isomaltose hypgather, stachyose, chitosan oligosaccharide, yeast beta-glucan, xanthan gum and edible essence, mixing uniformly to obtain a mixed solution, adding the mixed solution into a micro-jet device for treatment for 2 times, filtering the mixed solution after homogenization, and subpackaging the filtrate to obtain the composite prebiotic composition.
Example 3
The embodiment of the application provides a composite prebiotic composition for adjusting human intestinal function, which comprises the following raw materials in parts by weight: 40g of probiotic ferment fruit and vegetable juice, 20g of polydextrose, 20g of xylooligosaccharide, 20g of isomaltooligosaccharide, 15g of stachyose, 10g of chitosan oligosaccharide, 10g of yeast beta-glucan, 8 parts of xanthan gum and 3g of edible essence.
The probiotic ferment fruit and vegetable juice comprises the following raw materials: red date, longan, medlar, mulberry, blueberry, hawthorn, lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis.
The embodiment of the application provides a preparation process of a composite prebiotic composition for regulating the intestinal function of a human body, which comprises the following steps:
step A: selecting fresh and non-rotten red dates, medlar, longan, mulberry, blueberry and hawthorn, cleaning, pulping into juice by using a pulping machine, filtering by using a 80-mesh filter screen to obtain composite fruit juice, and sterilizing the fruit juice at 105-110 ℃ for 10-30s to obtain fruit and vegetable juice;
and B: respectively performing activation culture on lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis at 30 ℃ for 48 hours, and performing amplification culture at 32 ℃ for 72 hours to obtain fermentation liquor of each strain;
and C: stirring fruit and vegetable juice and fermentation liquor of each strain uniformly, standing and fermenting for 24-36h at 23 ℃ to obtain probiotic ferment fruit and vegetable juice, adding polydextrose, xylooligosaccharide, isomaltooligosaccharide, stachyose, chitosan oligosaccharide, yeast beta-glucan, xanthan gum and edible essence, mixing uniformly to obtain a mixed solution, adding the mixed solution into a microfluidization device for treating for 2 times, homogenizing the mixed solution, filtering, and subpackaging filtrate to obtain the composite prebiotics composition.
Example 4
The embodiment of the application provides a composite prebiotic composition for adjusting human intestinal function, which comprises the following raw materials in parts by weight: 55g of probiotic ferment fruit and vegetable juice, 25g of polydextrose, 22g of xylooligosaccharide, 20g of isomaltooligosaccharide, 18g of stachyose, 13g of chitosan oligosaccharide, 10g of yeast beta-glucan, 8 parts of xanthan gum and 3g of edible essence.
The probiotic ferment fruit and vegetable juice comprises the following raw materials: red date, longan, medlar, mulberry, blueberry, hawthorn, lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis.
The embodiment of the application provides a preparation process of a composite prebiotic composition for regulating the intestinal function of a human body, which comprises the following steps:
step A: selecting fresh and non-rotten red dates, medlar, longan, mulberry, blueberry and hawthorn, cleaning, pulping into juice by using a pulping machine, filtering by using a 80-mesh filter screen to obtain composite fruit juice, and sterilizing the fruit juice at 105-110 ℃ for 10-30s to obtain fruit and vegetable juice;
and B: respectively performing activated culture on lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis at 35 ℃ for 45 hours, and performing amplification culture at 33 ℃ for 64 hours to obtain fermentation liquor of each strain;
step C: stirring the fruit and vegetable juice and the fermentation liquor of each strain uniformly, standing and fermenting for 24-36h at 25 ℃ to obtain probiotic ferment fruit and vegetable juice, adding polydextrose, xylooligosaccharide, isomaltose hypgather, stachyose, chitosan oligosaccharide, yeast beta-glucan, xanthan gum and edible essence, mixing uniformly to obtain a mixed solution, adding the mixed solution into a micro-jet device for treatment for 2 times, filtering the mixed solution after homogenization, and subpackaging the filtrate to obtain the composite prebiotic composition.
Examples of the experiments
200 volunteers with the age of 24-52 years, the BMI of 24-30 and the body fat percentage (23-30% for males and 29-35% for females) are selected as test objects, and the test objects exclude females in gestational period and patients with severe gastrointestinal tract diseases and diabetic ketosis in nearly three months. The test subjects were randomly and evenly divided into 4 groups of 50 subjects each, and the test subjects kept their diet habits during the test period without taking hypoglycemic and hypolipidemic drugs.
Examples 1-4 of the present invention were administered to 4 groups of test subjects, respectively, using the following methods: 10 g/time, 2 times daily, and is administered with warm water of 40 deg.C for 1 month continuously. The evaluation index of the curative effect is as follows: the change in body fat percentage of the test subjects before and after the test was recorded, and the body fat change rate = (pre-test body fat percentage-post-test body fat percentage)/pre-test body fat percentage × 100% was calculated. The evaluation standard of the curative effect is as follows: the body fat change rate is more than or equal to 5 percent; effective, the change rate of body fat is more than or equal to 1 percent and less than 5 percent; ineffective, body fat change rate < 1%; the total effective rate is counted with obvious effect and effective effect. The test results are shown in table 1:
TABLE 1 test results
The test subjects complete the test process, no gastrointestinal discomfort is caused in the taking process, no adverse reactions such as diarrhea and flatulence are caused, and the daily excretion rule is regular in the taking process. Meanwhile, the probiotic has a good fat reducing effect, the probiotics is beneficial to fat burning, and the fat rate is reduced, so that the risk of diabetes and the like is reduced.
To sum up, the embodiment of the application provides a compound prebiotics composition for regulating human intestinal function, contains multiple dietary fibers, and the multiple dietary fibers not only promote the product to the proliferation of intestinal flora and the balance of flora structure, but also increase the stability of intestinal mucosa barrier, strengthen the functions of macrophages and natural killer cells, further promote the immune defense ability of human body, and then prevent and control obesity, reduce the occurrence of obesity complications, and have no adverse reactions such as diarrhea, flatulence and the like in the taking process.
The embodiment of the application provides a preparation of a compound prebiotic composition, and the preparation of the compound prebiotic composition is a liquid preparation. The liquid preparation is convenient to take and is more beneficial to absorption.
The embodiment of the application provides a preparation process of a composite probiotic composition for regulating the intestinal function of a human body, wherein the mixed solution is treated by a micro-jet device, and the dispersibility and the associativity of each component in the probiotic composition can be improved, so that the intestinal function regulation of the probiotic composition is further improved.
The embodiment of the application provides application of a composite prebiotic composition in preparation of food and/or health care products for regulating intestinal functions of human bodies. Can effectively regulate the intestinal function of human body, influence the metabolism of host by regulating intestinal flora, further prevent and control obesity and reduce obesity complications.
The embodiments described above are some, but not all embodiments of the present application. The detailed description of the embodiments of the present application is not intended to limit the scope of the claimed application, but is merely representative of selected embodiments of the application. All other embodiments obtained by a person of ordinary skill in the art based on the embodiments in the present application without making any creative effort belong to the protection scope of the present application.
Claims (10)
1. The composite prebiotic composition for regulating the intestinal function of a human body is characterized by comprising the following raw materials in parts by weight:
40-60 parts of probiotic ferment fruit and vegetable juice, 20-30 parts of polydextrose, 20-25 parts of xylooligosaccharide, 20-25 parts of isomaltooligosaccharide, 15-20 parts of stachyose, 10-15 parts of chitosan oligosaccharide, 10-12 parts of yeast beta-glucan, 8-10 parts of xanthan gum and 3-5 parts of edible essence.
2. The complex prebiotic composition for regulating human intestinal function of claim 1 wherein the probiotic ferment fruit and vegetable juice comprises the following raw materials:
red date, longan, medlar, mulberry, blueberry, hawthorn, lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis.
3. The compound prebiotic composition for regulating the intestinal function of the human body according to claim 1, which comprises the following raw materials in parts by weight:
40 parts of probiotic ferment fruit and vegetable juice, 20 parts of polydextrose, 20 parts of xylooligosaccharide, 20 parts of isomaltooligosaccharide, 15 parts of stachyose, 10 parts of chitosan oligosaccharide, 10 parts of yeast beta-glucan, 8 parts of xanthan gum and 3 parts of edible essence.
4. The compound prebiotic composition for regulating the intestinal function of the human body according to claim 1, which comprises the following raw materials in parts by weight:
60 parts of probiotic ferment fruit and vegetable juice, 30 parts of polydextrose, 25 parts of xylo-oligosaccharide, 25 parts of isomaltose oligosaccharide, 20 parts of stachyose, 15 parts of chitosan oligosaccharide, 12 parts of yeast beta-glucan, 10 parts of xanthan gum and 5 parts of edible essence.
5. A formulation of a complex prebiotic composition according to any of claims 1 to 4, wherein the formulation of the complex prebiotic composition is a liquid formulation.
6. A process for the preparation of a complex prebiotic composition for the modulation of intestinal function in humans according to any one of claims 1 to 5 comprising the steps of:
step A: selecting fresh and non-rotten red dates, medlar, longan, mulberry, blueberry and hawthorn, cleaning, pulping into juice by using a pulping machine, filtering by using a 80-mesh filter screen to obtain composite fruit juice, and sterilizing the fruit juice at 105-110 ℃ for 10-30s to obtain fruit and vegetable juice;
and B: respectively activating and culturing lactobacillus casei, lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus plantarum and bifidobacterium lactis, and then carrying out expanded culture to obtain fermentation liquor of each strain;
and C: stirring the fruit and vegetable juice and fermentation liquor of each strain uniformly, standing for fermentation to obtain probiotic ferment fruit and vegetable juice, adding polydextrose, xylooligosaccharide, isomaltooligosaccharide, stachyose, chitosan oligosaccharide, yeast beta-glucan, xanthan gum and edible essence, mixing uniformly to obtain a mixed solution, adding the mixed solution into a microfluidics device for treatment for 2 times, filtering the mixed solution after homogenization, and subpackaging the filtrate to obtain the composite probiotic composition.
7. The preparation process of the complex prebiotic composition for regulating the human intestinal function according to claim 6, wherein the activation culture condition in the step B is 30-37 ℃ for 36-48h.
8. The preparation process of the complex prebiotic composition for regulating the human intestinal function according to claim 6, wherein the condition of the expanded culture in the step B is 32-38 ℃ and the time is 60-72h.
9. The process for preparing a complex prebiotic composition for regulating the human intestinal function according to claim 6, wherein in the step C, the standing fermentation conditions are as follows: the temperature is 23-25 ℃, and the time is 24-36h.
10. Use of a complex prebiotic composition according to any of claims 1-9 in the manufacture of a food and/or health care product for the modulation of intestinal function in humans.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211070558.8A CN115349585A (en) | 2022-09-02 | 2022-09-02 | Composite prebiotic composition for regulating human intestinal function, preparation process and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211070558.8A CN115349585A (en) | 2022-09-02 | 2022-09-02 | Composite prebiotic composition for regulating human intestinal function, preparation process and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115349585A true CN115349585A (en) | 2022-11-18 |
Family
ID=84006097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211070558.8A Pending CN115349585A (en) | 2022-09-02 | 2022-09-02 | Composite prebiotic composition for regulating human intestinal function, preparation process and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115349585A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116019226A (en) * | 2022-12-14 | 2023-04-28 | 青岛琛蓝生物营养技术有限公司 | Chitosan oligosaccharide prebiotic composition for relaxing bowel and enhancing immunity and application thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104397818A (en) * | 2014-10-27 | 2015-03-11 | 庄小恩 | Multifunctional compound health care solid beverage and preparation method thereof |
| CN105815640A (en) * | 2016-03-31 | 2016-08-03 | 山东龙力生物科技股份有限公司 | Digestion-promoting and intestine-and-stomach-adjusting fruit-and-vegetable probiotic product and preparing method thereof |
| CN106901115A (en) * | 2017-03-22 | 2017-06-30 | 张红霞 | A kind of hawthorn blueberry juice beverage and preparation method thereof |
| CN107981128A (en) * | 2017-12-18 | 2018-05-04 | 绿杰股份有限公司 | A kind of production method of compound fermentative lactobacillus fruit-vegetable juice beverage |
| CN108094816A (en) * | 2018-01-19 | 2018-06-01 | 湖南康琪壹佰生物科技有限公司 | A kind of pectase solid beverage and preparation method thereof |
| CN111685332A (en) * | 2020-05-19 | 2020-09-22 | 北京美信高科科技有限责任公司 | Composition with fat-reducing, body-shaping and body-beautifying functions and preparation method thereof |
| WO2021136426A1 (en) * | 2019-12-31 | 2021-07-08 | 深圳富佑细胞生物技术股份有限公司 | Composite beverage and preparation method therefor |
| CN113331335A (en) * | 2021-05-28 | 2021-09-03 | 湖北明德医疗科技有限责任公司 | Prebiotic composition, solid beverage and preparation method of solid beverage |
| CN114246222A (en) * | 2021-12-29 | 2022-03-29 | 宁波御坊堂生物科技有限公司 | Plant-based yoghourt with functions of calming nerves, helping sleep and improving gastrointestinal tract and preparation method thereof |
-
2022
- 2022-09-02 CN CN202211070558.8A patent/CN115349585A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104397818A (en) * | 2014-10-27 | 2015-03-11 | 庄小恩 | Multifunctional compound health care solid beverage and preparation method thereof |
| CN105815640A (en) * | 2016-03-31 | 2016-08-03 | 山东龙力生物科技股份有限公司 | Digestion-promoting and intestine-and-stomach-adjusting fruit-and-vegetable probiotic product and preparing method thereof |
| CN106901115A (en) * | 2017-03-22 | 2017-06-30 | 张红霞 | A kind of hawthorn blueberry juice beverage and preparation method thereof |
| CN107981128A (en) * | 2017-12-18 | 2018-05-04 | 绿杰股份有限公司 | A kind of production method of compound fermentative lactobacillus fruit-vegetable juice beverage |
| CN108094816A (en) * | 2018-01-19 | 2018-06-01 | 湖南康琪壹佰生物科技有限公司 | A kind of pectase solid beverage and preparation method thereof |
| WO2021136426A1 (en) * | 2019-12-31 | 2021-07-08 | 深圳富佑细胞生物技术股份有限公司 | Composite beverage and preparation method therefor |
| CN111685332A (en) * | 2020-05-19 | 2020-09-22 | 北京美信高科科技有限责任公司 | Composition with fat-reducing, body-shaping and body-beautifying functions and preparation method thereof |
| CN113331335A (en) * | 2021-05-28 | 2021-09-03 | 湖北明德医疗科技有限责任公司 | Prebiotic composition, solid beverage and preparation method of solid beverage |
| CN114246222A (en) * | 2021-12-29 | 2022-03-29 | 宁波御坊堂生物科技有限公司 | Plant-based yoghourt with functions of calming nerves, helping sleep and improving gastrointestinal tract and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116019226A (en) * | 2022-12-14 | 2023-04-28 | 青岛琛蓝生物营养技术有限公司 | Chitosan oligosaccharide prebiotic composition for relaxing bowel and enhancing immunity and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Topping et al. | Resistant starch as a prebiotic and synbiotic: state of the art | |
| Qiang et al. | Health benefit application of functional oligosaccharides | |
| CN104642870B (en) | A kind of prebiotic compositions | |
| JP5911424B2 (en) | Bifidobacterium longum ATCCBAA-999 (BL999) and weight control | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CA2499665C (en) | Use of carbohydrates and compositions thereof for the treatment or prevention of diseases caused by imbalanced colon fermentation | |
| CN102065872A (en) | Probiotics to improve gut microbiota | |
| CN105639631A (en) | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide | |
| CN105722514A (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section | |
| CN111802550A (en) | Probiotic formula beverage and preparation method thereof | |
| CN106690331A (en) | Kelp dietary fiber granules and preparation method thereof | |
| CN108283285A (en) | A kind of health-care physiotherapeutic food of diabetes | |
| CN111227261A (en) | Prebiotic composition and application thereof | |
| CN113854360A (en) | Probiotic freeze-dried powder and preparation method thereof | |
| CN102845695B (en) | Konjac fermented food and beverage and preparation method thereof | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| CN115349585A (en) | Composite prebiotic composition for regulating human intestinal function, preparation process and application thereof | |
| CN1294849C (en) | Recipe for food fibers, prepn. method for said fibers | |
| CN113598231A (en) | Sucrose-free yogurt added with composite dietary fiber and humanized probiotics and preparation method thereof | |
| CN112931883A (en) | Prebiotic composition and preparation method and application thereof | |
| CN112167639A (en) | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof | |
| Saville et al. | Functional attributes and health benefits of novel prebiotic oligosaccharides derived from xylan, arabinan, and mannan | |
| CN116584597A (en) | Western Mei Yinpin formula for improving intestinal functions and preparation method thereof | |
| Chen et al. | A prebiotic formula improves the gastrointestinal bacterial flora in toddlers | |
| CN113197305A (en) | Formula and preparation method of crude fiber composite solid food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |